What is GANX's current stock price?

GANX (Gain Therapeutics, Inc.) is currently trading at $1.78 with a market cap of $75.9M.

What sector is Gain Therapeutics, Inc. in?

Gain Therapeutics, Inc. (GANX) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is GANX a good stock to buy?

Analysts have a Buy consensus on GANX with a price target of $9.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

GANX Gain Therapeutics, Inc.

Healthcare

$1.78+1.71%ClosedMarket Cap: $75.9M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

5.37

P/S

0.00

EV/EBITDA

-3.05

DCF Value

$0.61

FCF Yield

-25.5%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-201.4%

ROA

-113.3%

ROIC

-131.6%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-5.6M	$—
Q4 null	$0.00	$-4.5M	$—
FY null	$0.00	$-20.2M	$—
Q3 null	$0.00	$-5.3M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$9.00

Target (Median)

$9.00

Target Range

$8.00 - $10.00

1 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2025-12-19

BTIGBuy

2025-10-15

HC Wainwright & Co.Buy

2025-10-13

Maxim GroupBuy

2025-10-07

BTIGBuy

2025-09-08

Trading Activity

Insider Trades

View All

Mack Genedirector, officer: CEO, President

SellThu Mar 26

Fuggetta Gianlucaofficer: See Remark

SellThu Mar 26

Riley Jeffrey Scottdirector

SellWed Jun 25

RICHMAN ERIC Idirector

SellWed Jun 25

Nicaise Claudedirector

SellWed Jun 25

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.15

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.

Peers